Ownership and insider activity for Celldex Therapeutics, Inc. (CLDX): recent transactions by executives and directors. Track how corporate insiders are trading the stock.
Celldex Therapeutics, Inc. is a biopharmaceutical company dedicated to developing antibody-based treatments, specifically monoclonal and bispecific antibodies, for a range of diseases. Their pipeline features therapeutic candidates aimed at both inflammatory conditions and various forms of cancer. Among their key clinical programs: CDX-0159 is a Phase I monoclonal antibody designed to bind to and inhibit the activity of the KIT receptor tyrosine kinase.
Price
| Price | $29.71 (closing price, November 3, 2026) |
| Market Cap | $2.3B |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-06-25 | Lawver Teri L | A-Award | 90,000 | $3.1M |
| 2026-06-25 | Jimenez Freddy A. | A-Award | 93,000 | $3.2M |
| 2026-06-25 | Young Diane C. | A-Award | 57,000 | $1.9M |
| 2026-06-25 | Heath-Chiozzi Margo | A-Award | 95,000 | $3.2M |
| 2026-06-25 | Martin Samuel Bates | A-Award | 93,000 | $3.2M |
| 2026-06-25 | Cavanaugh Sarah | A-Award | 95,000 | $3.2M |
| 2026-06-25 | Crowley Elizabeth | A-Award | 100,000 | $3.4M |
| 2026-06-25 | PEPIN RONALD | A-Award | 20,000 | $682K |
| 2026-06-25 | KELER TIBOR | A-Award | 115,000 | $3.9M |
| 2026-06-25 | Marucci Anthony S | A-Award | 375,000 | $12.8M |
Balance Sheet (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $42.5M | $40.3M | $24.3M | $11.2M | $43.8M | $39.1M | $29.4M | $34.8M | $28.4M | $28.9M |
| Short-term Investments | $147.3M | $99.1M | $69.7M | $53.0M | $150.6M | $369.1M | $275.5M | $386.9M | $696.9M | $489.7M |
| Receivables | $1.8M | $1.9M | $3.2M | $1.2M | $1.8M | $172,000 | $347,000 | $4.5M | $700,000 | $2.0M |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $195.6M | $144.8M | $99.1M | $66.7M | $197.8M | $410.8M | $317.7M | $431.7M | $747.2M | $534.7M |
| Property, Plant & Equipment | $13.2M | $10.4M | $6.1M | $7.5M | $7.3M | $6.5M | $7.7M | $6.6M | $8.2M | $7.8M |
| Goodwill | $91.0M | $91.0M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | $81.5M | $67.6M | $50.6M | $48.7M | $30.7M | $27.2M | $27.2M | $27.2M | $27.2M | $27.2M |
| Total Assets | $383.4M | $315.6M | $155.8M | $122.9M | $235.8M | $444.7M | $352.7M | $465.6M | $792.3M | $583.0M |
| Accounts Payable | $1.7M | $1.7M | $1.1M | $1.2M | $1.0M | $1.2M | $3.3M | $3.5M | $3.3M | $1.2M |
| Short-term Debt | 0 | $6.6M | $4.5M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Liabilities | $35.2M | $27.7M | $12.6M | $11.6M | $14.2M | $16.5M | $18.6M | $31.1M | $39.5M | $51.0M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | $117.9M | $79.3M | $31.7M | $28.9M | $26.5M | $25.2M | $26.5M | $36.5M | $45.3M | $55.8M |
| Retained Earnings | -$719.5M | -$812.5M | -$962.4M | -$1.01B | -$1.07B | -$1.14B | -$1.26B | -$1.40B | -$1.56B | -$1.81B |
| Total Equity | $265.4M | $236.4M | $124.1M | $94.0M | $209.4M | $419.5M | $326.2M | $429.2M | $747.0M | $527.2M |
| Total Debt | 0 | $6.6M | $4.5M | $3.7M | $3.5M | $3.0M | $4.0M | $2.5M | $3.8M | $2.3M |
| Net Debt | -$189.8M | -$132.9M | -$89.5M | -$60.5M | -$190.9M | -$405.2M | -$300.9M | -$419.2M | -$721.5M | -$516.2M |
| Working Capital | $160.3M | $117.0M | $86.5M | $55.1M | $183.6M | $394.3M | $299.1M | $400.6M | $707.7M | $483.7M |
Financial Health
| Debt / Equity | 0.01 |
| Current Ratio | 11.82 |
| Piotroski F-Score | 2 |
| Altman Z-Score | 14.43 |
Profitability
| Return on Equity | -52.36% |
| Return on Invested Capital | -45.10% |
| Return on Assets | -38.42% |
| Gross Margin | -56,850.89% |
| Operating Margin | -290,948.21% |
| Net Margin | -268,385.71% |
Related companies: IMNM · NRIX · XNCR · RCUS
Explore sector: Healthcare · Biotechnology
More sections of CLDX: Overview · Financials · Valuation · Estimates · Technical
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method · Companies that pass the Lynch method · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks